A phase I study of AT-101 with cisplatin and etoposide in patients with advanced solid tumors with an expanded cohort in extensive-stage small cell lung cancer

By Schelman William   Mohammed Tabraiz   Traynor Anne   Kolesar Jill   Marnocha Rebecca   Eickhoff Jens   Keppen Michael   Alberti Dona   Wilding George   Takebe Naoko   Liu Glenn  

Investigational New Drugs, Vol. 32, Iss. 2, 2014-04 ,pp. : 295-302

Springer Publishing Company

Access to resources Recommend Favorite

Pemetrexed plus either cisplatin or carboplatin are active and well tolerated first-line treatments of extensive-stage small-cell lung cancer

By  

Inpharma, Vol. 1, Iss. 1563, 2006-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Is there a Place for Bevacizumab in Patients with Extensive-Stage Small Cell Lung Cancer?

By  

Current Cancer Drug Targets, Vol. 16, Iss. 3, 2016-03 ,pp. : 209-214

Bentham Science Publishers

Access to resources Recommend Favorite

First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

By Leon Luis   Vázquez Sergio   Gracia José Manuel   Casal Joaquín   Lazaro Martín   Firvida José Luis   Amenedo Margarita   Santome Lucia   Macia Sonia  

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1389-1396

Informa Healthcare

Access to resources Recommend Favorite

The combination of irinotecan plus carboplatin has antitumour activity in non-small-cell lung cancer (NSCLC)

By  

Inpharma, Vol. 1, Iss. 1473, 2005-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite